Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cracks in the Estrogen Carcinogenesis of Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Enhanced Prediction of Absorption and Emission Wavelengths of Organic Compounds through Hybrid Graph Neural Network Architectures.

ACS omega·2025
Same author

The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.

Signal transduction and targeted therapy·2025
Same author

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Mar 6, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

10.2K

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.

Thaddeus S Block1, Tiffany I Murphy2, Pamela N Munster3

  • 1Corcept Therapeutics, Inc, Menlo Park, CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.

Cancer Management and Research
|March 16, 2017
PubMed
Summary

Glucocorticoid receptor (GR) is present in all evaluated solid tumors. This validated assay allows standardized GR expression comparison across malignancies, potentially serving as a biomarker for targeted therapies.

Keywords:
glucocorticoid receptor expressionimmunohistochemistrysolid tumors

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
06:05

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

10.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

10.2K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
06:05

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

10.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Glucocorticoid receptor (GR) activity influences human physiology and chemotherapy resistance in solid tumors.
  • A validated immunohistochemistry (IHC) assay for GR immunoreactivity was previously developed for triple-negative breast cancer.
  • This study applies the validated IHC assay to assess GR expression across diverse solid tumor types.

Purpose of the Study:

  • To investigate the standardized application of a validated IHC assay for assessing GR expression.
  • To evaluate GR immunoreactivity in a broad spectrum of solid tumor malignancies.

Main Methods:

  • Analysis of 236 archived formalin-fixed paraffin-embedded tumor samples from 20 different solid tumor types.
  • Immunohistochemical staining to assess nuclear GR expression.
  • Quantification of GR staining using the H-score method, considering intensity (0-3+) and percentage of stained cells.

Main Results:

  • Glucocorticoid receptor (GR) was expressed in all evaluated solid tumor types.
  • Renal cell carcinoma, sarcoma, cervical cancer, and melanoma exhibited the highest mean H-scores, indicating high GR expression.
  • Colon, endometrial, and gastric cancers showed lower GR staining percentages and intensities, resulting in the lowest mean H-scores.

Conclusions:

  • A validated IHC assay successfully demonstrated GR immunoreactivity across all studied solid tumors.
  • The assay enables standardized comparison of GR expression levels among different malignancies.
  • Baseline GR expression levels may serve as a valuable biomarker for pharmaceutical targeting in research and clinical settings.